Promising AML combo trial halted early – what we know
NCT ID NCT04435691
First seen May 01, 2026 · Last updated May 11, 2026 · Updated 1 time
Summary
This study tested a new drug combo (magrolimab, azacitidine, and venetoclax) in 110 adults with acute myeloid leukemia (AML) that had come back or not responded to treatment. The goal was to find the best dose and see if the drugs could control the cancer. The trial was stopped early, but researchers measured how many patients achieved complete remission and how long they lived without the disease getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.